» Articles » PMID: 21962263

Does the Timing of Esophagectomy After Chemoradiation Affect Outcome?

Abstract

Background: After neoadjuvant chemoradiation (CXRT) for esophageal cancer, surgery has traditionally been recommended to be performed within 8 weeks. However, surgery is often delayed for various reasons. Data from other cancers suggest that delaying surgery may increase the pathologic complete response rate. However, there are theoretical concerns that waiting longer after radiation may lead to a more difficult operation and more complications. The optimal timing of esophagectomy after CXRT is unknown.

Methods: From a prospective database, we analyzed 266 patients with resected esophageal cancer who were treated with neoadjuvant CXRT from 2002 to 2008. Salvage resections were excluded from this analysis. We compared patients who had surgery within 8 weeks of CXRT and those who had surgery after 8 weeks. We used multivariable analysis to determine whether increased interval between chemoradiation and surgery was independently associated with perioperative complication, pathologic response, or overall survival.

Results: One hundred fifty patients were resected within 8 weeks and 116 were resected greater than 8 weeks after completing CXRT. Mean length of operation, intraoperative blood loss, anastomotic leak rate, and perioperative complication rate were similar for the two groups. Pathologic complete response rate and overall survival were also similar for the two groups (p=not significant). In multivariable analysis, timing of surgery was not an independent predictor of perioperative complication, pathologic complete response, or overall survival.

Conclusions: The timing of esophagectomy after neoadjuvant CXRT is not associated with perioperative complication, pathologic response, or overall survival. It may be reasonable to delay esophagectomy beyond 8 weeks for patients who have not yet recovered from chemoradiation.

Citing Articles

Early thoracic surgery consultation and location of therapy impact time to esophagectomy.

Deeb A, Dezube A, Lozano A, Singh A, De Leon L, Kucukak S J Thorac Dis. 2024; 16(9):5615-5623.

PMID: 39444915 PMC: 11494582. DOI: 10.21037/jtd-24-316.


Impact of the interval between neoadjuvant immunotherapy and surgery on prognosis in esophageal squamous cell carcinoma (ESCC): a real-world study.

Yang G, Hong Y, Zhang X, Zeng C, Tan L, Zhang X Cancer Immunol Immunother. 2024; 73(10):202.

PMID: 39105817 PMC: 11303633. DOI: 10.1007/s00262-024-03787-2.


Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.

Sabatelle R, Colson Y, Sachdeva U, Grinstaff M Mol Pharm. 2024; 21(7):3103-3120.

PMID: 38888089 PMC: 11331583. DOI: 10.1021/acs.molpharmaceut.4c00246.


Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?.

Liu J, Zhu L, Huang X, Lu Z, Wang Y, Yang Y J Cancer Res Clin Oncol. 2024; 150(3):161.

PMID: 38536527 PMC: 10972911. DOI: 10.1007/s00432-024-05696-4.


Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysis.

Karthyarth M, Mathew A, Ramachandra D, Goyal A, Yadav N, Reddy K Esophagus. 2023; 20(3):390-401.

PMID: 36800076 DOI: 10.1007/s10388-023-00989-y.


References
1.
Tulchinsky H, Shmueli E, Figer A, Klausner J, Rabau M . An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008; 15(10):2661-7. DOI: 10.1245/s10434-008-9892-3. View

2.
Delanian S, Lefaix J . Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007; 17(2):99-107. DOI: 10.1016/j.semradonc.2006.11.006. View

3.
Burmeister B, Smithers B, Gebski V, Fitzgerald L, Simes R, Devitt P . Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005; 6(9):659-68. DOI: 10.1016/S1470-2045(05)70288-6. View

4.
Tran C, Udani S, Holt A, Arnell T, Kumar R, Stamos M . Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg. 2006; 192(6):873-7. DOI: 10.1016/j.amjsurg.2006.08.061. View

5.
Swisher S, Wynn P, Putnam J, Mosheim M, Correa A, Komaki R . Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002; 123(1):175-83. DOI: 10.1067/mtc.2002.119070. View